Table 1.
Drug sensitivities of HL‐60, HL/CAFdA20 and HL/CAFdA80
| IC50 (nM) | |||
|---|---|---|---|
| HL‐60 | HL/CAFdA20 | HL/CAFdA80 | |
| Clofarabine | 22.5 | 451.4 (20.0) | 1775.0 (79.0) |
| Cytarabine | 17.6 | 10 001.0 (568.0)a | ND |
| Gemcitabine | 3.3 | 35.3 (11.0)a | 1124.0 (341.0)a |
| Cladribine | 4.1 | 373.0 (91.0)a | 1825.0 (445.0)a |
| F‐ara‐A | 113.0 | 217.0 (1.9)n.s. | 489.0 (4.3)a |
| Doxorubicin | 57.4 | 98.1 (1.7)n.s. | 323.0 (5.6)a |
| Vincristine | 28.3 | 33.3 (1.2)n.s. | 30.9 (1.1)n.s. |
| Etoposide | 79.7 | 93.3 (1.2)n.s. | 153.0 (1.9)n.s. |
| ABT737 | 63.8 | 294.0 (4.6)n.s. | 1135.0 (18.0)n.s. |
a
*P < 0.01. Exponential growing cells (HL‐60, HL/CAFdA20 and HL/CAFdA80) were exposed to increasing concentrations of a given anticancer agent as indicated for 72 h. The number in the parentheses is the relative resistance, which was obtained by dividing the IC50 value of HL/CAFdA20 or HL/CAFdA80 by that of HL‐60. F‐ara‐A, fludurabine nucleoside; ND, not determined because the IC50 values were beyond the upper detection limit.